Información de Briacell Therapeutics Corp, dividendo de Briacell Therapeutics Corp, actividades de los accionistas y más

Información de Briacell Therapeutics Corp Compañía

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Información de la empresa

Código de la empresaBCTX

Nombre de la empresaBriacell Therapeutics Corp

Fecha de salida a bolsaOct 12, 2006

Fundada en2006

Director ejecutivoDr. William V. Williams, M.D.

Número de empleados17

Tipo de títulosOrdinary Share

Fin del año fiscalOct 12

DirecciónSuite 300 - Bellevue Centre, 235 -15th Street

CiudadWEST VANCOUVER

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísCanada

Código postalV7T 2X1

Teléfono16049211810

Sitio Webhttps://briacell.com/

Código de la empresaBCTX

Fecha de salida a bolsaOct 12, 2006

Fundada en2006

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionados

Cambio

Dr. William V. Williams, M.D.

President, Chief Executive Officer, Director

10.81K

+2.10%

Mr. Jamieson Bondarenko

Non-Executive Independent Chairman of the Board

10.77K

+34.77%

Mr. Vaughn C. Embro-pantalony, CPA

Independent Director

1.19K

+22.93%

Mr. Gadi Levin

Chief Financial Officer, Corporate Secretary

187.00

--

Mr. Martin E. Schmieg, CPA

Independent Director

--

Dr. Rebecca A. Taub, M.D.

Independent Director

--

-100.00%

Dr. Giuseppe Del Priore, M.D.

Chief Medical Officer

--

-100.00%

Dr. Jane A. Gross, Ph.D.

Independent Director

--

-100.00%

Dr. Miguel A. Lopez-Lago

Chief Scientific Officer

--

-100.00%

Nombre

Nombre/Posición

Posición

Accionados

Cambio

Dr. William V. Williams, M.D.

President, Chief Executive Officer, Director

10.81K

+2.10%

Mr. Jamieson Bondarenko

Non-Executive Independent Chairman of the Board

10.77K

+34.77%

Mr. Vaughn C. Embro-pantalony, CPA

Independent Director

1.19K

+22.93%

Mr. Gadi Levin

Chief Financial Officer, Corporate Secretary

187.00

--

Mr. Martin E. Schmieg, CPA

Independent Director

--

Dr. Rebecca A. Taub, M.D.

Independent Director

--

-100.00%

Desglose de ingresos

No datos encontrados

No datos encontrados

Por negocio

Por región

No datos encontrados

Accionista

Hora de actualización: dom., 23 de feb

Estadísticas de accionistas

Tipo

Estadísticas de accionistas

Accionista

Proporción

3I Management LLC

9.95%

L5 Capital Inc.

4.69%

Lynwood Capital Management Inc.

2.87%

Copia Fund (Cayman) LP

1.47%

Williams (William V)

0.29%

Other

80.73%

Estadísticas de accionistas

Accionista

Proporción

3I Management LLC

9.95%

L5 Capital Inc.

4.69%

Lynwood Capital Management Inc.

2.87%

Copia Fund (Cayman) LP

1.47%

Williams (William V)

0.29%

Other

80.73%

Tipo

Accionista

Proporción

Family Office

9.95%

Corporation

6.16%

Investment Advisor/Hedge Fund

2.89%

Investment Advisor

0.67%

Individual Investor

0.62%

Research Firm

0.47%

Hedge Fund

0.03%

Bank and Trust

0.01%

Other

79.19%

Participación institucional

Hora de actualización: sáb., 22 de feb

Periodo de informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q1

65

403.53K

10.88%

-198.25K

2024Q4

65

403.53K

10.88%

-198.25K

2024Q3

64

441.30K

30.40%

+131.88K

2024Q2

63

437.48K

31.09%

+121.43K

2024Q1

62

332.09K

21.52%

-17.16K

2023Q4

67

402.86K

34.69%

+35.57K

2023Q3

74

369.20K

35.11%

-158.11K

2023Q2

84

434.95K

41.59%

-338.84K

2023Q1

83

423.04K

40.96%

-355.97K

2022Q4

78

427.52K

41.39%

-334.82K

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

3I Management LLC

369.00K

9.95%

+369.00K

--

Feb 05, 2025

L5 Capital Inc.

174.03K

4.69%

+4.50K

+2.65%

Dec 10, 2024

Lynwood Capital Management Inc.

106.52K

2.87%

+1.14K

+1.08%

Mar 31, 2024

Copia Fund (Cayman) LP

54.56K

1.47%

+54.56K

--

Dec 29, 2023

Williams (William V)

10.81K

0.29%

+222.00

+2.10%

Dec 09, 2024

Bondarenko (Jamieson)

10.77K

0.29%

+2.78K

+34.77%

Dec 09, 2024

Bank Vontobel AG

7.33K

0.2%

+2.00K

+37.50%

Dec 31, 2024

Group One Trading, L.P.

4.53K

0.12%

+2.00K

+79.18%

Dec 31, 2024

Cantor Fitzgerald, L.P

3.73K

0.1%

+3.73K

--

Dec 31, 2024

Susquehanna International Group, LLP

3.37K

0.09%

+2.45K

+263.97%

Dec 31, 2024

ETF relacionados

Nombre

Proporción

No datos encontrados

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

No datos encontrados

División de acciones

Fecha

Tipo

Relación

Jan 03, 2025

Merger

15<1

Jan 03, 2025

Merger

15<1

Jan 03, 2025

Merger

15<1

Jan 03, 2025

Merger

15<1

Fecha

Tipo

Relación

Jan 03, 2025

Merger

15<1

Jan 03, 2025

Merger

15<1

Jan 03, 2025

Merger

15<1

Jan 03, 2025

Merger

15<1

Briacell Therapeutics Corp

6.800USD

Briacell Therapeutics Corp

6.800

Descripción general

Compañía